All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit Know AML.
The AML Hub uses cookies on this website. They help us give you the best online experience. By continuing to use our website without changing your cookie settings, you agree to our use of cookies in accordance with our updated Cookie Policy
Introducing
Now you can personalise
your AML Hub experience!
Bookmark content to read later
Select your specific areas of interest
View content recommended for you
Find out moreThe AML Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the AML Hub cannot guarantee the accuracy of translated content. The AML Hub and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.
Visual abstract | Azacitidine with venetoclax and magrolimab in patients with ND or R/R AML
Bookmark this article
The AML Hub is pleased to present a visual abstract summarizing the key results from a phase I/II trial investigating the combination of azacitidine, venetoclax, and magrolimab for the treatment of patients with newly diagnosed or relapsed/refractory acute myeloid leukemia. These data were recently presented by Naval Daver at the 64th American Society of Hematology (ASH) Annual Meeting and Exposition and offers a rationale for further investigation of magrolimab within triplet combination therapy for patients with acute myeloid leukemia.
Related articles
Newsletter
Subscribe to get the best content related to AML delivered to your inbox